BMY
BRISTOL-MYERS SQUIBB (BMY) Halts Phase 3 Mavacamten Trial for Lack of Efficacy
The company terminated its Phase 3 study of mavacamten in non-obstructive hypertrophic cardiomyopathy after the drug failed to show short-term efficacy.
BMY
Market-moving news on Bristol Myers Squibb (NYSE: BMY): filings, earnings, deals and other events, from REDFILED.